SCHEMBL4516266

SCHEMBL4516266

CC(C)(C)OC(=O)N(c1ccc(-c2ccncc2)cc1)[C@H](Cc1ccc([N+](=O)[O-])cc1)C(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.38
CDC7 O00311 1/20 0.37
CYP17A1 P05093 1/20 0.37
NR1D1 P20393 1/20 0.36
ALDH1A1 P00352 4/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
ITGA4 P13612 1/20 0.35
ITGB7 P26010 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
MAPT P10636 5/20 0.34
KMT2A Q03164 3/20 0.34
PKM P14618 1/20 0.34
ROCK1 Q13464 1/20 0.34
ATM Q13315 1/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
MEN1 O00255 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4533235 0.87 CYP17A1 (0.39) CYP17A1ITGA4ROCK1
SCHEMBL4514379 0.86 GRM2 (0.41) CYP17A1ALDH1A1L3MBTL1KMT2AROCK1
SCHEMBL4517315 0.86 ROCK2 (0.44) CYP17A1PPARGPPARAROCK1
SCHEMBL4527461 0.86 GRM2 (0.41) CYP17A1ALDH1A1L3MBTL1KMT2AROCK1
SCHEMBL4519180 0.85 GPR142 (0.41) NPC1CDC7CYP17A1ALDH1A1MAPT
SCHEMBL4526796 0.85 KIF11 (0.39) CYP17A1ROCK1
SCHEMBL4523329 0.83 GPR142 (0.40) POLBCYP17A1FNTAFNTB
SCHEMBL4516262 0.82 MC4R (0.39) NPC1SMN1; SMN2POLBCDC7CYP17A1
SCHEMBL7782926 0.79 PPARG (0.41) NPC1SMN1; SMN2NR1D1ALDH1A1PPARG
SCHEMBL4524959 0.79 ROCK1 (0.51) CDC7ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211919-B2 Amide derivatives as rock inhibitors ASTELLAS PHARMA INC. (JP) 2012-07-03 US disclosed
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2009-04-23 US disclosed
EP-1922306-A2 AMIDE DERIVATIVES AS ROCK INHIBITORS Astellas Pharma Inc. (JP) 2008-05-21 EP disclosed
WO-2007026920-A2 AMIDE DERIVATIVES AS ROCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ROCK1, ROCK2, RHOA NPC1 1693/4885SMN1; SMN2 3046/4885POLB 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.